CDC Implements Travel Screening and Entry Rules for Ebola Outbreak
Federal agencies began enhanced screening and entry restrictions on May 18, 2026, to limit the risk of Ebola disease caused by Bundibugyo virus entering the United States. The measures target travelers from Uganda, the Democratic Republic of the Congo, and South Sudan.
vox.comFederal agencies began enhanced screening and entry restrictions on May 18, 2026, to limit the risk of Ebola disease caused by Bundibugyo virus entering the United States. The Centers for Disease Control and Prevention, the Department of Homeland Security, and other federal agencies are applying the measures under authority from Sections 362 and 365 of the Public Health Service Act.
The order will remain in effect for 30 days.
Enhanced screening and traveler monitoring will apply to individuals arriving from affected areas. Non-U.S. Agencies will coordinate with airlines and port-of-entry officials to identify and manage travelers who may have been exposed. Port health protection, contact tracing, laboratory testing capacity, and hospital readiness will also be strengthened nationwide.
CDC assesses the immediate risk to the general U.S. public as low. Officials will continue to evaluate the situation and may adjust measures as new information becomes available. Travelers from affected countries are advised to monitor their health for 21 days after travel and seek medical care immediately if they develop fever, weakness, vomiting, diarrhea, or unexplained bleeding.
Key Facts
Potential Impact
- 01
Airlines and ports of entry will adjust procedures for travelers from affected countries.
- 02
Hospitals and laboratories will increase readiness and testing capacity nationwide.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…